These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 2614465)

  • 1. Beta-N-methylamino-L-alanine. Chronic oral administration is not neurotoxic to mice.
    Perry TL; Bergeron C; Biro AJ; Hansen S
    J Neurol Sci; 1989 Dec; 94(1-3):173-80. PubMed ID: 2614465
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical and neurobehavioral effects of neonatal administration of beta-N-methylamino-L-alanine and 3,3'-iminodipropionitrile.
    Dawson R; Marschall EG; Chan KC; Millard WJ; Eppler B; Patterson TA
    Neurotoxicol Teratol; 1998; 20(2):181-92. PubMed ID: 9536463
    [TBL] [Abstract][Full Text] [Related]  

  • 3. β-N-methylamino-l-alanine causes neurological and pathological phenotypes mimicking Amyotrophic Lateral Sclerosis (ALS): the first step towards an experimental model for sporadic ALS.
    de Munck E; Muñoz-Sáez E; Miguel BG; Solas MT; Ojeda I; Martínez A; Gil C; Arahuetes RM
    Environ Toxicol Pharmacol; 2013 Sep; 36(2):243-255. PubMed ID: 23688553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cycad neurotoxic amino acid, beta-N-methylamino-L-alanine (BMAA), elevates intracellular calcium levels in dissociated rat brain cells.
    Brownson DM; Mabry TJ; Leslie SW
    J Ethnopharmacol; 2002 Oct; 82(2-3):159-67. PubMed ID: 12241991
    [TBL] [Abstract][Full Text] [Related]  

  • 5. l-Serine Reduces Spinal Cord Pathology in a Vervet Model of Preclinical ALS/MND.
    Davis DA; Cox PA; Banack SA; Lecusay PD; Garamszegi SP; Hagan MJ; Powell JT; Metcalf JS; Palmour RM; Beierschmitt A; Bradley WG; Mash DC
    J Neuropathol Exp Neurol; 2020 Apr; 79(4):393-406. PubMed ID: 32077471
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.
    Chernoff N; Hill DJ; Diggs DL; Faison BD; Francis BM; Lang JR; Larue MM; Le TT; Loftin KA; Lugo JN; Schmid JE; Winnik WM
    J Toxicol Environ Health B Crit Rev; 2017; 20(4):1-47. PubMed ID: 28598725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Billion-fold difference in the toxic potencies of two excitatory plant amino acids, L-BOAA and L-BMAA: biochemical and morphological studies using mouse brain slices.
    Pai KS; Shankar SK; Ravindranath V
    Neurosci Res; 1993 Aug; 17(3):241-8. PubMed ID: 7901822
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Beyond Guam: the cyanobacteria/BMAA hypothesis of the cause of ALS and other neurodegenerative diseases.
    Bradley WG; Mash DC
    Amyotroph Lateral Scler; 2009; 10 Suppl 2():7-20. PubMed ID: 19929726
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lack of behavioral and neuropathological effects of dietary beta-methylamino-L-alanine (BMAA) in mice.
    Cruz-Aguado R; Winkler D; Shaw CA
    Pharmacol Biochem Behav; 2006 Jun; 84(2):294-9. PubMed ID: 16808967
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The cyanobacterial amino acid β-N-methylamino-l-alanine perturbs the intermediary metabolism in neonatal rats.
    Engskog MK; Karlsson O; Haglöf J; Elmsjö A; Brittebo E; Arvidsson T; Pettersson C
    Toxicology; 2013 Oct; 312():6-11. PubMed ID: 23886855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stereospecific acute neuronotoxicity of 'uncommon' plant amino acids linked to human motor-system diseases.
    Nunn PB; Seelig M; Zagoren JC; Spencer PS
    Brain Res; 1987 May; 410(2):375-9. PubMed ID: 3109690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Single Neonatal Exposure to BMAA in a Rat Model Produces Neuropathology Consistent with Neurodegenerative Diseases.
    Scott LL; Downing TG
    Toxins (Basel); 2017 Dec; 10(1):. PubMed ID: 29286334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BMAA selectively injures motor neurons via AMPA/kainate receptor activation.
    Rao SD; Banack SA; Cox PA; Weiss JH
    Exp Neurol; 2006 Sep; 201(1):244-52. PubMed ID: 16764863
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Detection of cyanobacterial neurotoxin β-N-methylamino-l-alanine within shellfish in the diet of an ALS patient in Florida.
    Banack SA; Metcalf JS; Bradley WG; Cox PA
    Toxicon; 2014 Nov; 90():167-73. PubMed ID: 25123936
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycad β-N-methylamino-L-alanine (BMAA), methylazoxymethanol, genotoxicity, and neurodegeneration.
    Spencer PS; Palmer VS; Kisby GE
    Toxicon; 2018 Dec; 155():49-50. PubMed ID: 30316979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotoxicity of beta-N-methylamino-L-alanine (BMAA) and beta-N-oxalylamino-L-alanine (BOAA) on cultured cortical neurons.
    Weiss JH; Koh JY; Choi DW
    Brain Res; 1989 Sep; 497(1):64-71. PubMed ID: 2551452
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Specific antagonism of excitotoxic action of 'uncommon' amino acids assayed in organotypic mouse cortical cultures.
    Ross SM; Seelig M; Spencer PS
    Brain Res; 1987 Nov; 425(1):120-7. PubMed ID: 3123008
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BMAA and Neurodegenerative Illness.
    Cox PA; Kostrzewa RM; Guillemin GJ
    Neurotox Res; 2018 Jan; 33(1):178-183. PubMed ID: 28540663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomagnification of cyanobacterial neurotoxins and neurodegenerative disease among the Chamorro people of Guam.
    Cox PA; Banack SA; Murch SJ
    Proc Natl Acad Sci U S A; 2003 Nov; 100(23):13380-3. PubMed ID: 14612559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Morphometric and neurochemical alterations found in l-BMAA treated rats.
    de Munck E; Muñoz-Sáez E; Miguel BG; Solas MT; Martínez A; Arahuetes RM
    Environ Toxicol Pharmacol; 2015 May; 39(3):1232-45. PubMed ID: 26002186
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.